AKERO THERAPEUTICS INC. - COMMON STOCK

36,73

04-апреля-25 16:45:00

15 мин. задержка

Акции

-3,26

-8,15%

Сегодняшний диапазон

36,69 - 39,99

ISIN

N/A

Источник

NASDAQ

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

10 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

08 май 2024 07:00:01 Источник Nasdaq GlobeNewswire
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

30 апр 2024 08:00:01 Источник Nasdaq GlobeNewswire
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

08 мар 2024 16:02:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

07 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics Announces Pricing of Public Offering of Common Stock

05 мар 2024 21:13:56 Источник Nasdaq GlobeNewswire
Akero Therapeutics Announces Proposed Public Offering of Common Stock

04 мар 2024 16:21:12 Источник Nasdaq GlobeNewswire
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

04 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

29 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

29 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 08:15:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program

18 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

13 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023

10 ноя 2023 08:57:33 Источник Nasdaq GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

08 ноя 2023 07:00:01 Источник Nasdaq GlobeNewswire
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

17 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

10 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

09 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology

04 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September

31 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.